Removing the exocrine pancreas may improve blood sugar control and insulin production.
Loss of the Exocrine Pancreas Improves Glucose Tolerance and Insulin Secretion
This study is looking at how losing part of the pancreas affects blood sugar control and insulin production in people with Type 2 diabetes, using a special mouse model to help find new ways to manage the condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10884285 on NIH RePORTER |
What this research studies
This research investigates how the loss of the exocrine pancreas affects glucose tolerance and insulin secretion, particularly in the context of Type 2 diabetes (T2D). Using a specialized mouse model, researchers will explore the relationship between the exocrine pancreas and insulin-producing beta cells, aiming to understand how this interaction influences blood sugar levels. The study involves surgical techniques to ablate the exocrine pancreas while preserving the islets, allowing for a focused examination of their function. Patients may benefit from insights gained that could lead to new treatment strategies for managing T2D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 2 diabetes or prediabetes, particularly those struggling with insulin secretion issues.
Not a fit: Patients with Type 1 diabetes or those without any form of diabetes may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly improve blood sugar control for patients with Type 2 diabetes.
How similar studies have performed: While the specific approach of ablating the exocrine pancreas is novel, previous studies have shown promising results in understanding the pancreas's role in glucose metabolism.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Saleh, Mohamed — University of Pittsburgh at Pittsburgh
- Study coordinator: Saleh, Mohamed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.